134 related articles for article (PubMed ID: 33132906)
1. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects.
Zhang H; Wu M; Zhu X; Li C; Li X; Sun J; Liu C; Liu Q; Wei W; Niu J; Ding Y
Front Pharmacol; 2020; 11():01329. PubMed ID: 33132906
[TBL] [Abstract][Full Text] [Related]
2. The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.
Hou J; Hu Z; Xu W; Di Y; Song C; Wu F; Liu J; Guo Y
Int Immunopharmacol; 2022 Jun; 107():108666. PubMed ID: 35286913
[TBL] [Abstract][Full Text] [Related]
3. Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study.
Lin Y; Yang H; Yang X; Guo C; Yang S; Yang G; Wu Q; Pan C; Sun C; Li C; He L; Huang J; Pei Q
Expert Opin Investig Drugs; 2022 Oct; 31(10):1125-1132. PubMed ID: 36112084
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects.
Ding Y; Liu Y; Dou C; Guo S
J Bone Oncol; 2023 Oct; 42():100499. PubMed ID: 37701913
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males.
Vogg B; Poetzl J; El Galta R; Fuhr R; Schwebig A; Sekhar S
Expert Opin Biol Ther; 2024; 24(1-2):91-100. PubMed ID: 38269652
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects.
Chen H; Chen W; Yuan F; Guo Q; Zhang X; Wang C; Li X
Front Pharmacol; 2022; 13():821944. PubMed ID: 35140619
[No Abstract] [Full Text] [Related]
7. Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects.
Zhang H; Li C; Liu J; Wu M; Li X; Zhu X; Li Q; Wang B; Mao Y; Ding Y; Jin Q
Expert Opin Investig Drugs; 2021 Feb; 30(2):185-192. PubMed ID: 33306418
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial.
Li H; Huang Y; Chen Z; Zeng A; Zhang H; Yu Y; Wei S; Li Q; Wang X; Wang X; Wang X; Yang R; Dai X; Bi M; Sun T; Zhang Q; Han C; Li Y; Kang X; Liu Y; Zhang L
BioDrugs; 2023 Mar; 37(2):259-269. PubMed ID: 36802320
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
Guo Y; Guo T; Di Y; Xu W; Hu Z; Xiao Y; Yu H; Hou J
Expert Opin Biol Ther; 2023; 23(8):705-715. PubMed ID: 36892190
[TBL] [Abstract][Full Text] [Related]
10. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
Zhang H; Li Q; Zhu X; Li C; Li X; Liu C; Hu Y; Chen G; Wei H; Wang J; Shen Z; Ding Y
Cancer Chemother Pharmacol; 2018 Oct; 82(4):615-623. PubMed ID: 30043208
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects.
Wang S; Yang X; Huang J; Yang S; Wu Q; Chen H; Wu S; Dou C; Yang G; Xiang Y
Expert Opin Investig Drugs; 2022 Oct; 31(10):1133-1142. PubMed ID: 36045484
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of a new biosimilar trastuzumab (HL02): a Phase I bioequivalence study in healthy Chinese men.
Zhang H; Liu T; Wu M; Wei H; Li C; Li X; Liu J; Chen H; Ding Y; Liu L
Expert Opin Biol Ther; 2022 Feb; 22(2):179-186. PubMed ID: 33616478
[TBL] [Abstract][Full Text] [Related]
13. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects.
Zhang H; Chen H; Li X; Wu M; Zhu X; Li C; Liu J; Wei H; Hu Y; Wang J; Yang Y; Zhu X; Ding Y
Front Pharmacol; 2021; 12():646171. PubMed ID: 34122068
[No Abstract] [Full Text] [Related]
14. A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra
Zhang H; Li X; Liu J; Li C; Wu M; Zhu X; Sun J; Fang M; Ding Y
Ann Med; 2021 Dec; 53(1):375-383. PubMed ID: 33629921
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
Expert Opin Biol Ther; 2024 Feb; ():1-9. PubMed ID: 38349618
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men.
Zhang H; Wang H; Wei H; Chen H; Liu J; Li C; Zhu X; Li X; Yu J; Zhou Y; Yang X; Wang Z; Wu M; Ding Y
Front Pharmacol; 2020; 11():609522. PubMed ID: 33569002
[No Abstract] [Full Text] [Related]
17. A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects.
Gao L; Li Q; Zhang H; Wu M; Fang M; Yang L; Li X; Liu J; Li C; Chen H; Zhu X; Ding Y; Zhou M
Front Pharmacol; 2021; 12():675358. PubMed ID: 34084144
[No Abstract] [Full Text] [Related]
18. LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA
Cao G; Wang J; He J; Hu Y; Yang H; Que L; Gu X; Yu J; Wu X; Wu J; Fang W; He Q; Zhang J
Front Pharmacol; 2023; 14():1111893. PubMed ID: 37081963
[No Abstract] [Full Text] [Related]
19. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
Singh I; Attrey A; Garg A; Patel R; Jose V
Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
[TBL] [Abstract][Full Text] [Related]
20. A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers.
Wang J; Qi L; Liu L; Wang Z; Chen G; Wang Y; Liu X; Liu Y; Liu H; Tong Y; Liu C; Lei C; Wang X
Front Pharmacol; 2019; 10():905. PubMed ID: 31474863
[No Abstract] [Full Text] [Related]
[Next] [New Search]
